Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Gin S Malhi, Erica Bell, Maedeh Jadidi, Michael Gitlin, Michael Bauer
For over half a century, it has been widely known that lithium is the most efficacious treatment for bipolar disorder. Yet, despite this, its prescription has consistently declined over this same period of time. A number of reasons for this apparent disparity between evidence and clinical practice have been proposed, including a lack of confidence amongst clinicians possibly because of an absence of training and lack of familiarity with the molecule. Simultaneously, competition has grown within the pharmacological armamentarium for bipolar disorder with newer treatments promoting an image of being safer and easier to prescribe primarily because of not necessitating plasma monitoring, which understandably is appealing to patients who then exercise their preferences accordingly...
August 26, 2023: International Journal of Bipolar Disorders
#22
JOURNAL ARTICLE
Kanita Dervic, Leo Sher, Hanga C Galfalvy, Michael Grunebaum, Ainsley K Burke, Gregory Sullivan, M Elizabeth Sublette, J John Mann, Maria A Oquendo
OBJECTIVE: Our group reported previously a comparable overall antisuicidal effect of lithium and valproate in bipolar patients. We investigated factors associated with higher antisuicidal efficacy of lithium in older individuals. METHODS: The age-related antisuicidal effect of lithium and valproate was compared in ninety-four (n = 94) high-risk bipolar suicide attempters who participated in a 2.5-year randomized, double-blind trial. RESULTS: Age significantly moderated the effect of lithium vs...
August 22, 2023: Journal of Affective Disorders
#23
JOURNAL ARTICLE
Maurizio Pompili, Isabella Berardelli, Salvatore Sarubbi, Elena Rogante, Luca Germano, Giuseppe Sarli, Denise Erbuto, Ross J Baldessarini
BACKGROUND: Preventing hospitalization of major affective disorder patients is a fundamental clinical challenge for which lithium is expected to be helpful. METHODS: We compared hospitalization rates and morbidity of 260 patients with DSM-5 bipolar or major depressive disorder in the 12 months before starting lithium versus 12 months of its use. We evaluated duration of untreated illness, previous treatments, substance abuse, suicidal status, lithium dose, and use of other medicines for association with new episodes of illness or of symptomatic worsening as well as hospitalization, using bivariate and multivariate analyses...
August 7, 2023: Journal of Affective Disorders
#24
JOURNAL ARTICLE
Should we consider adding low-dose lithium to our diet to prevent cognitive decline and suicidality?
Isabella Pacchiarotti, Anna Giménez-Palomo, Joaquim Radua
No abstract text is available yet for this article.
July 26, 2023: Neuroscience and Biobehavioral Reviews
#25
Jingyuan Zhou, Yuan Cao, Gaoju Deng, Jinbo Fang, Changjian Qiu
BACKGROUND: Reversible splenial lesion syndrome (RESLES) is a rare neurological condition characterized by temporary abnormalities in the splenium of the corpus callosum, which has been reported in mental disorders. Previous studies on bipolar disorder (BD) primarily focused on aspects such as brain structure and function, neurochemical changes, and genetics. However, there have been no studies reporting the occurrence of this syndrome during hypomanic episodes and its disappearance during the remission phase in bipolar disorder type 2 (BD-II)...
2023: Frontiers in Psychiatry
#26
Marisol Herrera-Rivero, Karina Gutiérrez-Fragoso, Anbupalam Thalamuthu, Azmeraw T Amare, Mazda Adli, Kazufumi Akiyama, Nirmala Akula, Raffaella Ardau, Bárbara Arias, Jean-Michel Aubry, Lena Backlund, Frank Bellivier, Antonio Benabarre, Susanne Bengesser, Bhattacharjee Abesh, Joanna Biernacka, Armin Birner, Micah Cearns, Pablo Cervantes, Hsi-Chung Chen, Caterina Chillotti, Sven Cichon, Scott Clark, Francesc Colom, Cristiana Cruceanu, Piotr Czerski, Nina Dalkner, Franziska Degenhardt, Maria Del Zompo, J Raymond DePaulo, Bruno Etain, Peter Falkai, Ewa Ferensztajn-Rochowiak, Andreas J Forstner, Josef Frank, Louise Frisen, Mark Frye, Janice Fullerton, Carla Gallo, Sebastien Gard, Julie Garnham, Fernando Goes, Maria Grigoroiu-Serbanescu, Paul Grof, Ryota Hashimoto, Roland Hasler, Joanna Hauser, Urs Heilbronner, Stefan Herms, Per Hoffmann, Liping Hou, YiHsiang Hsu, Stéphane Jamain, Esther Jiménez, Jean-Pierre Kahn, Layla Kassem, Tadafumi Kato, John Kelsoe, Sarah Kittel-Schneider, Po-Hsiu Kuo, Joachim Kurtz, Ichiro Kusumi, Barbara König, Gonzalo Laje, Mikael Landén, Catharina Lavebratt, Marion Leboyer, Susan Leckband, Mario Maj, Mirko Manchia, Cynthia Marie-Claire, Lina Martinsson, Michael McCarthy, Susan L McElroy, Vincent Millischer, Marina Mitjans, Francis Mondimore, Palmiero Monteleone, Caroline Nievergelt, Tomas Novak, Markus Nöthen, Claire Odonovan, Norio Ozaki, Sergi Papiol, Andrea Pfennig, Claudia Pisanu, James Potash, Andreas Reif, Eva Reininghaus, Hélène Richard-Lepouriel, Gloria Roberts, Guy Rouleau, Janusz K Rybakowski, Martin Schalling, Peter Schofield, Klaus Oliver Schubert, Eva Schulte, Barbara Schweizer, Giovanni Severino, Tatyana Shekhtman, Paul Shilling, Kazutaka Shimoda, Christian Simhandl, Claire Slaney, Alessio Squassina, Thomas Stamm, Pavla Stopkova, Fabian Streit, Fasil Ayele, Alfonso Tortorella, Gustavo Turecki, Julia Veeh, Eduard Vieta, Biju Viswanath, Stephanie Witt, Peter Zandi, Martin Alda, Michael Bauer, Francis McMahon, Philip Mitchell, Marcella Rietschel, Thomas Schulze, Bernhard Baune
The link between bipolar disorder (BP) and immune dysfunction remains controversial. While epidemiological studies have long suggested an association, recent research has found only limited evidence of such a relationship. To clarify this, we investigated the contributions of immune-relevant genetic factors to the response to lithium (Li) treatment and the clinical presentation of BP. First, we assessed the association of a large collection of immune-related genes (4,925) with Li response, defined by the Retrospective Assessment of the Lithium Response Phenotype Scale (Alda scale), and clinical characteristics in patients with BP from the International Consortium on Lithium Genetics (ConLi + Gen, N = 2,374)...
June 26, 2023: Research Square
#27
JOURNAL ARTICLE
Angela W S Fung, Kenneth I Shulman, Danijela Konforte, Hilde Vandenberghe, Julia Stemp, Victoria R Yuan, Paul M Yip, Lei Fu
Lithium is the first-line treatment for maintenance therapy in bipolar disorder. It is an effective mood stabilizer agent, and may have potential benefits in neuroprotection and reducing the risk of suicide. Toxicity has been a concern in recent decades, particularly in older adults (≥60 years). In 2019, the Older Adults Task Force within the International Society for Bipolar Disorder (ISBD) published recommendations for age-stratified lithium therapeutic ranges for therapy of Older Age Bipolar Disorder (OABD), namely 0...
July 2023: EJIFCC
#28
JOURNAL ARTICLE
Giulio Emilio Brancati, Abraham Nunes, Katie Scott, Claire O'Donovan, Pablo Cervantes, Paul Grof, Martin Alda
BACKGROUND: The distinction between bipolar I and bipolar II disorder and its treatment implications have been a matter of ongoing debate. The aim of this study was to examine differences between patients with bipolar I and II disorders with particular emphasis on the early phases of the disorders. METHODS: 808 subjects diagnosed with bipolar I (N = 587) or bipolar II disorder (N = 221) according to DSM-IV criteria were recruited between April 1994 and March 2022 from tertiary-level mood disorder clinics...
July 14, 2023: International Journal of Bipolar Disorders
#29
JOURNAL ARTICLE
Carolina V Hernandorena, Ross J Baldessarini, Leonardo Tondo, Gustavo H Vázquez
LEARNING OBJECTIVES AFTER PARTICIPATING IN THIS CME ACTIVITY, THE PSYCHIATRIST SHOULD BE BETTER ABLE TO: • Analyze and compare the different bipolar disorder (BD) types.• Identify markers that distinguish BD types and explain how the DSM-IV defines the disorder. ABSTRACT: Since the status of type II bipolar disorder (BD2) as a separate and distinct form of bipolar disorder (BD) remains controversial, we reviewed studies that directly compare BD2 to type I bipolar disorder (BD1)...
July 2023: Harvard Review of Psychiatry
#30
JOURNAL ARTICLE
Jan Sarlon, Timo Partonen, Undine E Lang
Circadian desynchronizations are associated with psychiatric disorders as well as with higher suicidal risk. Brown adipose tissue (BAT) is important in the regulation of body temperature and contributes to the homeostasis of the metabolic, cardiovascular, skeletal muscle or central nervous system. BAT is under neuronal, hormonal and immune control and secrets batokines: i.e., autocrine, paracrine and endocrine active substances. Moreover, BAT is involved in circadian system. Light, ambient temperature as well as exogen substances interact with BAT...
2023: Frontiers in Neuroscience
#31
JOURNAL ARTICLE
Martin Plöderl, Florian Naudet
No abstract text is available yet for this article.
June 20, 2023: International Clinical Psychopharmacology
#32
JOURNAL ARTICLE
Charlotte Hauge, Christopher Rohde, Søren D Østergaard
BACKGROUND: Postpartum psychotic- or mood disorders are psychiatric emergencies associated with risk of suicide and infanticide. Except from case reports, there are only few descriptions of its treatment. Therefore, we aimed to describe the treatment of women admitted with postpartum psychotic- or mood disorder in Denmark with emphasis on the use of electroconvulsive therapy (ECT). METHODS: We conducted a register-based cohort study of all women with incident postpartum psychotic- or mood disorder (no prior diagnoses of psychotic- or mood disorder or treatment with ECT) requiring admission in the period from 2011 to 2018...
June 20, 2023: Acta Psychiatrica Scandinavica
#33
JOURNAL ARTICLE
R Tabrisi, M D Harun-Rashid, J Montero, N Venizelos, M Msghina
RATIONALE: Availability of the dopamine and noradrenaline precursor tyrosine is critical for normal functioning, and deficit in tyrosine transport across cell membrane and the blood-brain barrier has been reported in bipolar disorder and schizophrenia. Clozapine and lithium are two psychoactive agents used to treat psychosis, mood disorders and suicidal behavior, but their mechanism of action remains largely unknown. OBJECTIVE: To characterize immediate and delayed differences in tyrosine uptake between healthy controls (HC) and bipolar patients (BP) and see if these differences could be normalized by either clozapine, lithium or both...
June 15, 2023: Psychopharmacology
#34
JOURNAL ARTICLE
Chikashi Takano, Masaki Kato, Naoto Adachi, Yukihisa Kubota, Takaharu Azekawa, Hitoshi Ueda, Kouji Edagawa, Eiichi Katsumoto, Eiichiro Goto, Seiji Hongo, Kazuhira Miki, Takashi Tsuboi, Norio Yasui-Furukori, Atsuo Nakagawa, Toshiaki Kikuchi, Koichiro Watanabe, Toshihiko Kinoshita, Reiji Yoshimura
OBJECTIVE: In patients with bipolar disorder (BD), rapid cycling (RC) presents a risk for a more severe illness, while euthymia (EUT) has a better prognosis. This study focused on the progression of RC and EUT, which are contrasting phenomenology, and aimed to clarify the influence of patient backgrounds and prescription patterns on these different progressions, using a large sample from the first and second iterations of a multicenter treatment survey for BD in psychiatric clinics (MUSUBI)...
2023: Frontiers in Psychiatry
#35
JOURNAL ARTICLE
Peter Andersson, Jussi Jokinen, Håkan Jarbin, Johan Lundberg, Adrian E Desai Boström
IMPORTANCE: The association of early diagnosis and management of bipolar disorder with adolescent suicide mortality (ASM) is unknown. OBJECTIVE: To assess regional associations between ASM and bipolar disorder diagnosis frequencies. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study investigated the association between annual regional ASM and bipolar disorder diagnosis rates in Swedish adolescents aged 15 to 19 years in January 1, 2008, through December 31, 2021...
May 24, 2023: JAMA Psychiatry
#36
JOURNAL ARTICLE
Samuel T Wilkinson, Daniel Trujillo Diaz, Zachary W Rupp, Anubhav Kidambi, Karina L Ramirez, José M Flores, Victor J Avila-Quintero, T Greg Rhee, Mark Olfson, Michael H Bloch
BACKGROUND: Suicide is a public health crisis. We conducted a systematic review and meta-analysis of the effects of psychopharmacologic and somatic therapies on suicide risk. METHODS: A systematic search of MEDLINE for studies evaluating the effects of pharmacologic (excluding antidepressants) or somatic interventions on suicide risk was conducted. Studies were included if they used a comparison group, reported on suicide death, assessed a psychopharmacological or somatic intervention, and included adults...
April 2023: Focus: Journal of Life Long Learning in Psychiatry
#37
JOURNAL ARTICLE
Joshua J Griffiths, Carlos A Zarate, J J Rasimas
We summarize outcomes for several pharmacologic and neurostimulatory approaches that have been considered potential treatments to reduce suicide risk, namely, by reducing suicide deaths, attempts, and ideation in various clinical populations. Available treatments include clozapine, lithium, antidepressants, antipsychotics, electroconvulsive therapy, and transcranial magnetic stimulation. The novel repurposing of ketamine as a potential suicide risk-mitigating agent in the acute setting is also discussed. Research pathways to better understand and treat suicidal ideation and behavior from a neurobiological perspective are proposed in light of this foundation of information and the limitations and challenges inherent in suicide research...
April 2023: Focus: Journal of Life Long Learning in Psychiatry
#38
REVIEW
Sidney Zisook, Isabel Domingues, Jason Compton
Suicide is a leading cause of death that is often preventable. This article reviews the role of medications in treating suicidal behavior and in preventing suicide. For an acute suicidal crisis, ketamine, and perhaps esketamine, are emerging as important tools. For patients with chronic suicidality, clozapine remains the only U.S. Food and Drug Administration (FDA) approved antisuicidal medication, and its use is predominantly for patients with schizophrenia and schizoaffective disorder. An abundance of literature supports the use of lithium among patients with mood disorders, including those with major depressive disorder...
April 2023: Focus: Journal of Life Long Learning in Psychiatry
#39
REVIEW
Katie Scott, Abraham Nunes, Barbara Pavlova, Sandra Meier, Martin Alda
BACKGROUND: Genetic studies of bipolar disorder (BD) have shown varied results, which is in part because of the heterogeneity of the disorder. Identifying clinical phenotypes of BD could reduce variability and benefit research. Since BD has a robust genetic component, studies can investigate clinical traits that cluster in families to identify phenotypes with a probable genetic basis. METHODS: We conducted a systematic review of the current literature on familial clinical traits of BD...
August 2023: Acta Psychiatrica Scandinavica
#40
Ilaria Secci, Lucie Petigas, Alexandra Cuenod, Paul Klauser, Carole Kapp, Audrey Novatti, Marco Armando
High rates of co-occurring depression are commonly reported in youth with Autism Spectrum Disorder (ASD), especially in individuals without intellectual disability (ID). Depression in ASD undermines adaptive behavior and is associated with a higher risk of suicidality. Females with ASD may be particularly vulnerable due to their greater use of camouflaging strategies. Indeed, in comparison to males, ASD is underdiagnosed in females, despite higher rates of internalizing symptoms and suicidality. Trauma exposure may also play a role in the development of depressive symptoms in this population...
2023: Frontiers in Psychiatry
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
